Scynexis shares surge 12.06% intraday after FDA grants fast track and QIDP designations to drug candidate.

Scynexis Inc. surged 12.06% intraday following the U.S. Food and Drug Administration’s grant of Fast Track and Qualified Infectious Disease Product (QIDP) designations to its drug candidate. These regulatory designations accelerate development timelines and qualify the therapy for potential market exclusivity, enhancing the drug’s commercial viability. The move reflects regulatory confidence in Scynexis’ pipeline, bolstering investor optimism about its therapeutic innovation and market access potential.